HardEndocrinologyType 2 diabetes with cardiovascular diseaseau-amcau-racp
A 62-year-old man with long-standing type 2 diabetes and established coronary artery disease is on metformin and gliclazide. His HbA1c is 7.8% (62 mmol/mol) despite good adherence. eGFR is 70 mL/min/1.73 m² and BMI 33 kg/m². According to current Australian guidelines, which additional glucose-lowering agent is preferred for cardiovascular risk reduction?